Document is current
Any future updates will be listed below
-
Authors
Xiao, Haopeng https://orcid.org/0000-0002-4166-647X
Ordonez, Martha
Fink, Emma C.
Covington, Taylor A.
Woldemichael, Hilina B. https://orcid.org/0009-0005-7494-6127
Chen, Junyi https://orcid.org/0000-0001-7453-6623
Jain, Mika Sarkin
Rohatgi, Milan H. https://orcid.org/0009-0004-4426-4814
Wei, Shelley M. https://orcid.org/0009-0002-8359-1880
Burger, Nils
Sharif, Muneeb A.
Jan, Julius
Wang, Yaoyu https://orcid.org/0000-0002-0178-296X
Petrocelli, Jonathan J.
Blackmore, Katherine
Smythers, Amanda L. https://orcid.org/0000-0002-1552-6705
Zhang, Bingsen https://orcid.org/0000-0001-8119-1715
Gilbert, Matthew
Cheong, Hakyung https://orcid.org/0009-0001-3330-3126
Khetarpal, Sumeet A.
Smith, Arianne
Bogoslavski, Dina
Lei, Yu
Vaites, Laura Pontano
McAllister, Fiona E. https://orcid.org/0000-0002-7862-6711
Van Bruggen, Nick
Donovan, Katherine A.
Huttlin, Edward L. https://orcid.org/0000-0002-1822-1173
Mills, Evanna L. https://orcid.org/0000-0003-0447-8995
Fischer, Eric S.
Chouchani, Edward T. https://orcid.org/0000-0002-9776-8790
- License Information
-
More Information
Article History
Received: 31 July 2024
Accepted: 14 August 2025
First Online: 17 September 2025
Competing interests
: E.T.C. is co-founder and equity holder of Matchpoint Therapeutics and Aevum Therapeutics. E.S.F. is a founder, scientific advisory board member and equity holder of Civetta Therapeutics, Proximity Therapeutics, Neomorph Inc. (serving on the board of directors), Stelexis Biosciences Inc., Anvia Therapeutics Inc. (serving on the board of directors) and CPD4 Inc. (serving on the board of directors). E.S.F. is also an equity holder and scientific advisory board member for Avilar Therapeutics, Photys Therapeutics and Ajax Therapeutics and an equity holder in Lighthorse Therapeutics. E.S.F. is a consultant to Novartis, EcoR1 capital, Odyssey and Deerfield. The Fischer laboratory receives or has received research funding from Deerfield, Novartis, Ajax, Interline, Bayer and Astellas. K.A.D. receives or has received consulting fees from Neomorph Inc. and Kronos Bio. E.T.C., H.X. and M.O. have filed patents on LRRC58. The other authors declare no competing interests.
